Gabriela Martinez Ravn

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

David Russell‐Jones, Allan Vaag, O. Schmitz et al. · Diabetologia · 2009 · 829 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 Diabetes

Athena Philis‐Tsimikas, G. Charpentier, Per Clauson et al. · Clinical Therapeutics · 2006 · 279 citations

Medicine, Endocrinology, Pharmacotherapy +11

Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial

Gregory W. Albers, Rüdiger von Kummer, Thomas Truelsen et al. · The Lancet Neurology · 2015 · 121 citations

Medicine, Neurology, Pharmacotherapy +11

Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies

Steven P. Marso, Jason B. Lindsey, Joshua M. Stolker et al. · Diabetes and Vascular Disease Research · 2011 · 103 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Significantly Better Glycemic Control and Weight Reduction with Liraglutide, a Once-daily Human GLP-1 Analog, Compared with Insulin Glargine: All as Add-on to Metformin and a Sulfonylurea in Type 2 Diabetes.

O. Schmitz, David Russell‐Jones, Allan Vaag et al. · Canadian Journal of Diabetes · 2008 · 46 citations

Medicine, Pharmacology, Pharmacotherapy +15